144 related articles for article (PubMed ID: 20860621)
21. Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule.
Ando Y; Minami H; Saka H; Ando M; Sugiura S; Sakai S; Shimokata K
Jpn J Cancer Res; 1997 May; 88(5):517-21. PubMed ID: 9247610
[TBL] [Abstract][Full Text] [Related]
22. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate.
Dooley MJ; Poole SG; Rischin D; Webster LK
Eur J Cancer; 2002 Jan; 38(1):44-51. PubMed ID: 11750838
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
Holweger K; Lipp HP; Beijnen JH; Bokemeyer C; Hartmann JT
Cancer Chemother Pharmacol; 2011 Sep; 68(3):693-701. PubMed ID: 21136060
[TBL] [Abstract][Full Text] [Related]
24. Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance.
White-Koning M; Paludetto MN; Le Louedec F; Gladieff L; Chevreau C; Chatelut E; Puisset F
Cancer Chemother Pharmacol; 2020 Mar; 85(3):585-592. PubMed ID: 31915969
[TBL] [Abstract][Full Text] [Related]
25. Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert AH; Newell DR; Gumbrell LA; O'Reilly S; Burnell M; Boxall FE; Siddik ZH; Judson IR; Gore ME; Wiltshaw E
J Clin Oncol; 1989 Nov; 7(11):1748-56. PubMed ID: 2681557
[TBL] [Abstract][Full Text] [Related]
26. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.
Newell DR; Pearson AD; Balmanno K; Price L; Wyllie RA; Keir M; Calvert AH; Lewis IJ; Pinkerton CR; Stevens MC
J Clin Oncol; 1993 Dec; 11(12):2314-23. PubMed ID: 8246021
[TBL] [Abstract][Full Text] [Related]
27. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.
Herrington JD; Tran HT; Riggs MW
Cancer Chemother Pharmacol; 2006 Jan; 57(2):241-7. PubMed ID: 16133538
[TBL] [Abstract][Full Text] [Related]
28. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
[TBL] [Abstract][Full Text] [Related]
29. Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model.
Asai G; Ando Y; Saka H; Ando M; Sugiura S; Sakai S; Hasegawa Y; Shimokata K
Eur J Clin Pharmacol; 1998; 54(9-10):725-7. PubMed ID: 9923575
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.
Etienne MC; Leger F; Pivot X; Chatelut E; Bensadoun RJ; Guardiola E; Renée N; Magné N; Canal P; Milano G
Ann Oncol; 2003 Apr; 14(4):643-7. PubMed ID: 12649114
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.
van Warmerdam LJ; Rodenhuis S; ten Bokkel Huinink WW; Maes RA; Beijnen JH
Cancer Chemother Pharmacol; 1996; 37(3):266-70. PubMed ID: 8529288
[TBL] [Abstract][Full Text] [Related]
32. Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care.
McLean L; Whittle JR; Graham J; Ismail H; Lichtenstein M; Hicks RJ; McNally O; Herschtal A; Rosenthal M; Rischin D; Hamilton A
Gynecol Oncol; 2020 Jun; 157(3):793-798. PubMed ID: 32220419
[TBL] [Abstract][Full Text] [Related]
33. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
34. Estimation of renal function and its potential impact on carboplatin dosing in children with cancer.
Chinnaswamy G; Cole M; Boddy AV; Keir M; Price L; Parry A; English M; Veal GJ;
Br J Cancer; 2008 Sep; 99(6):894-9. PubMed ID: 18781149
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis.
Oguri T; Shimokata T; Inada M; Ito I; Ando Y; Sasaki Y; Hasegawa Y
Cancer Chemother Pharmacol; 2010 Sep; 66(4):813-7. PubMed ID: 20563583
[TBL] [Abstract][Full Text] [Related]
36. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
37. [Clinical evaluation of calculating carboplatin dosage using Japanese equation for estimating GFR for gynecologic cancer].
Kidera Y; Nakao M; Tsubaki M; Yoshinaga M; Kajitani F; Yanae M; Sakano M; Yamazoe Y; Chiba Y; Moriyama K; Nishida S
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1143-8. PubMed ID: 21772099
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer.
Sato E; Yano I; Jiko M; Takahashi K; Motohashi H; Masuda S; Katsura T; Nishiyama H; Segawa T; Ito N; Kamoto T; Ogawa O; Inui K
Biol Pharm Bull; 2006 Jul; 29(7):1441-4. PubMed ID: 16819185
[TBL] [Abstract][Full Text] [Related]
39. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.
Donadio C; Lucchesi A; Ardini M; Cosio S; Fanucchi A; Gadducci A
Ther Drug Monit; 2009 Feb; 31(1):63-9. PubMed ID: 19077927
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.
van Warmerdam LJ; Rodenhuis S; van der Wall E; Maes RA; Beijnen JH
Br J Cancer; 1996 Apr; 73(8):979-84. PubMed ID: 8611435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
